U.S. Government, Eli Lilly, and Novo Nordisk Announce Agreement to Lower GLP-1 Weight-Loss Drug Prices

(Source: Kechuang 100 ETF Fund)

U.S. Government, Eli Lilly and Company, Novo Nordisk Announce Agreement to Lower Prices of GLP-1 Weight Loss Drugs to $245 per Month; Both Companies to Receive FDA Priority Review Voucher (PRV); Prices of GLP-1s Also Reduced for Medicaid and Medicare Programs (Cailian Press)